Lung cancer treatment and palliation

December 2004
Thorax;Dec2004 Supplement, Vol. 59, p52
Academic Journal
The article presents some papers related to lung cancer treatment and palliation. Concurrent chemoradiotherapy may be the most effective form of treatment for some patients with locally advanced inoperable non-small cell lung cancer (NSCLC). The causative relationship between thoracic radiotherapy and both pneumonitis and pulmonary fibrosis is well recognized. Full pulmonary function studies on 20 long term survivors of were repeated in the treatment. It is concluded that in 47% of cases, pulmonary function improved after treatment, due to lasting control of bulky central tumors.


Related Articles

  • Hypofractionated Radiotherapy in Non Small Cell Lung Cancer: A Review of the Current Literature. Beli, I.; Koukourakis, G.; Platoni, K.; Tolia, M.; Kelekis, N.; Kouvaris, J.; Syrigos, C.; Mystakidou, K.; Varveris, C.; Kouloulias, V. // Reviews on Recent Clinical Trials;May2010, Vol. 5 Issue 2, p103 

    Hypofractionated irradiation has an established role in the palliative treatment of patients with advanced medically inoperable non - small cell lung cancer (NSCLC) and poor performance status. Also hypofractionated radiotherapy merits careful consideration in the curative treatment of patients...

  • Palliative higher-dose radiation improved overall survival in NSCLC.  // Hem/Onc Today;10/25/2008, Vol. 9 Issue 19, p29 

    The article discusses a study which showed improvement in the overall survival rate of patients with non-small cell lung cancer who were treated with higher-dose palliative thoracic radiation. Results for symptom palliation, overall survival, toxicity and re-irradiation rate were evaluated in...

  • Stereotactic body radiation therapy in the re-irradiation situation - a review. Mantel, Frederick; Flentje, Michael; Guckenberger, Matthias // Radiation Oncology;2013, Vol. 8 Issue 1, p1 

    Although locoregional relapse is frequent after definitive radiotherapy (RT) or multimodal treatments, re-irradiation is only performed in few patients even in palliative settings like e.g. vertebral metastasis. This is most due to concern about potentially severe complications, especially when...

  • Prophylactic cranial irradiation for patients with small-cell lung cancer. Bunn Jr., Paul A.; Kelly, Karen // JNCI: Journal of the National Cancer Institute;2/1/95, Vol. 87 Issue 3, p161 

    Editorial. Comments on prophylactic cranial irradiation for patients with small cell lung cancer. Histological differentiation between small cell lung cancer and non-small cell lung cancer; Reduction of central nervous system metastases rate with prophylactic irradiation; Stratification of...

  • Concurrent administration of Docetaxel and Stealth® liposomal doxorubicin with radiotherapy in non-small cell lung cancer: excellent tolerance using subcutaneous amifostine for cytoprotection. Koukourakis, M.I.; Romanidis, K.; Froudarakis, M.; Kyrgias, G.; Koukourakis, G.V.; Retalis, G.; Bahlitzanakis, N. // British Journal of Cancer;8/12/2002, Vol. 87 Issue 4, p385 

    The substantial augmentation of the radiation sequelae during chemo-radiotherapy with novel drugs masks the real potential of such regimens. In this study we examined whether subcutaneous administration of amifostine can reduce the toxicity of a highly aggressive chemo-radiotherapy scheme with...

  • POINT / COUNTER. Bin Teh; Loo Jr., Billy W. // Hem/Onc Today;6/10/2009, Vol. 10 Issue 11, p11 

    The article presents two different views on which is the better option for treating small cell lung cancer (SCLC), the high-dose thoracic radiation therapy with 60 Gy to 70 Gy or the standard of care.

  • Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Arriagada, Rodrigo; Le Chevalier, Thierry // JNCI: Journal of the National Cancer Institute;2/1/95, Vol. 87 Issue 3, p183 

    Evaluates the effects of prophylactic cranial irradiation on brain metastasis, overall survival and late-occurring toxic effects in patients with small-cell lung cancer in complete remission. Decrease in risk of brain metastasis; Possible beneficial effect on overall survival; Trial design;...

  • Topotecan.  // Reactions Weekly;12/16/2006, Issue 1132, p25 

    The article presents a case report on the adverse effect of topotecan on a 55-year-old man who had a history of pulmonary fibrosis and small cell lung cancer. The man developed diffuse alveolar damage after palliative treatment with topotecan. He received antibacterials, low molecular weight...

  • Surgery in limited-disease small-cell lung cancer. Koul, Parvaiz A. // Lung India;Jan-Mar2012, Vol. 29 Issue 1, p2 

    The author reflects on the abandonment of surgery as a treatment of choice for patients with limited-disease small-cell lung cancer (LD-SCLC) due to the result of a randomized trial which revealed a survival difference between surgery and radiotherapy. An overview of some studies which show that...


Read the Article


Sign out of this library

Other Topics